12-week study concludes that new cosmeceutical improves skin barrier function, erythema and lesions associated with rosacea
Napa, CA, May 4, 2009 – Senetek, PLC (OTCBB: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, today announced that the clinical study entitled “Topical PRK-124 (0.125%) Lotion for Improving the Signs and Symptoms of Rosacea,” has been published in the May issue of Journal of Drugs in Dermatology, a peer-reviewed dermatologic publication.
“We are extremely pleased that the University of California, Irvine, study has been published in the Journal of Drugs in Dermatology,” stated Frank Massino, Chairman and Chief Executive Officer of Senetek, PLC. “As one of the most highly-respected and well-read publications in the dermatologic field, there is no better means to substantiate and communicate this scientific advancement to physicians interested in rosacea.”
The 12-week, open-label study concludes that Pyratine XR™ (0.125% furfuryl tetrahydropyranyladenine) improved skin barrier function and the appearance of erythema (redness) and lesions (pustules and papules) associated with mild-to-moderate rosacea during 12 weeks of treatment.
According to study data, Pyratine XR™ produced a progressive decrease in the symptoms associated with rosacea, with an overall clinical improvement in 80% of subjects, including reduction of redness and lesions. Transepidermal water loss measurements showed a 22% decrease, which supports an improvement in skin barrier function, with a 41% mean improvement in skin dryness as early as week four. All subject self-assessments showed good tolerability and cosmetic acceptability.
“Current treatments for rosacea, like oral and topical antibiotics, possess long-term tolerability and other health concerns that affect the more than 14 million Americans suffering from rosacea,” said Dr. Arisa Ortiz, clinical research fellow and investigator on the Pyratine XR clinical research trial. “The study data is promising for rosacea sufferers and suggests that Pyratine XR can improve rosacea symptoms without adverse effects. The findings definitely warrant further research.”
To read the article in full, please visit www.jddonline.com or www.PyratineXR.com.
About Senetek, PLC
Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company’s extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company’s website at www.senetekplc.com.
1-707-226-3900 ext. 102
Media Contacts/Senetek, PLC:
Michael Rogers Public Relations
Maggie Carr/Michael Rogers
212-255-7210 ext. 22